Last updated: 2026-10-19 21:04:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Taysha Gene Therapies, Inc. (TSHA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.95, with a market capitalization of $1.18B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.46 to $7.30. This page covers its latest market performance, valuation, price trends and company information.
$1.18B | |
$3.66 | |
$33.35 | |
$0.50 | |
$3.62 | |
4.13M | |
3.34M | |
-- | |
$7.30 | |
$3.46 | |
-- | |
-- |
Taysha Gene Therapies, Inc. (TSHA) is trading at $3.95 in after-hours trading as of 2026-10-19 20:44:00, up 8.98% ($0.32) from the regular-session close of $3.62.
After-hours trading shows how investors are pricing TSHA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Taysha Gene Therapies, Inc. (TSHA) moved from $4.43 to $3.95, representing a decline of 10.95% ($0.48).
The stock traded between $3.46 and $4.57 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 4.49 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 12.7%
TSHA is currently trading at $3.95, placing it 12.7% of the way from its 52-week low of $3.46 to its 52-week high of $7.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 99 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Taysha Gene Therapies, Inc. (TSHA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.